Cargando…

Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes

INTRODUCTION: We conducted this study to compare the risk of pneumonia between thiazolidinedione (TZD) use and nonuse in persons with type 2 diabetes (T2D). METHODS: We identified 46,763 propensity-score matched TZD users and nonusers from Taiwan’s National Health Insurance Research Database between...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Fu-Shun, Wei, James Cheng-Chung, Hung, Yu-Tung, Hsu, Chung Y., Hwu, Chii-Min, Hsu, Chih-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981669/
https://www.ncbi.nlm.nih.gov/pubmed/36876083
http://dx.doi.org/10.3389/fmicb.2023.1118000
_version_ 1784900157997842432
author Yen, Fu-Shun
Wei, James Cheng-Chung
Hung, Yu-Tung
Hsu, Chung Y.
Hwu, Chii-Min
Hsu, Chih-Cheng
author_facet Yen, Fu-Shun
Wei, James Cheng-Chung
Hung, Yu-Tung
Hsu, Chung Y.
Hwu, Chii-Min
Hsu, Chih-Cheng
author_sort Yen, Fu-Shun
collection PubMed
description INTRODUCTION: We conducted this study to compare the risk of pneumonia between thiazolidinedione (TZD) use and nonuse in persons with type 2 diabetes (T2D). METHODS: We identified 46,763 propensity-score matched TZD users and nonusers from Taiwan’s National Health Insurance Research Database between January 1, 2000, and December 31, 2017. The Cox proportional hazards models were used for comparing the risk of morbidity and mortality associated with pneumonias. RESULTS: Compared with the nonuse of TZDs, the adjusted hazard ratios (95% CI) for TZD use in hospitalization for all-cause pneumonia, bacterial pneumonia, invasive mechanical ventilation, and death due to pneumonia were 0.92 (0.88–0.95), 0.95 (0.91–0.99), 0.80 (0.77–0.83), and 0.73 (0.64–0.82), respectively. The subgroup analysis revealed that pioglitazone, not rosiglitazone, was associated with a significantly lower risk of hospitalization for all-cause pneumonia [0.85 (0.82–0.89)]. Longer cumulative duration and higher cumulative dose of pioglitazone were associated with further lower adjusted hazard ratios in these outcomes compared to no-use of TZDs. DISCUSSION: This cohort study demonstrated that TZD use was associated with significantly lower risks of hospitalization for pneumonia, invasive mechanical ventilation, and death due to pneumonia in patients with T2D. Higher cumulative duration and dose of pioglitazone were associated with a further lower risk of outcomes.
format Online
Article
Text
id pubmed-9981669
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99816692023-03-04 Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes Yen, Fu-Shun Wei, James Cheng-Chung Hung, Yu-Tung Hsu, Chung Y. Hwu, Chii-Min Hsu, Chih-Cheng Front Microbiol Microbiology INTRODUCTION: We conducted this study to compare the risk of pneumonia between thiazolidinedione (TZD) use and nonuse in persons with type 2 diabetes (T2D). METHODS: We identified 46,763 propensity-score matched TZD users and nonusers from Taiwan’s National Health Insurance Research Database between January 1, 2000, and December 31, 2017. The Cox proportional hazards models were used for comparing the risk of morbidity and mortality associated with pneumonias. RESULTS: Compared with the nonuse of TZDs, the adjusted hazard ratios (95% CI) for TZD use in hospitalization for all-cause pneumonia, bacterial pneumonia, invasive mechanical ventilation, and death due to pneumonia were 0.92 (0.88–0.95), 0.95 (0.91–0.99), 0.80 (0.77–0.83), and 0.73 (0.64–0.82), respectively. The subgroup analysis revealed that pioglitazone, not rosiglitazone, was associated with a significantly lower risk of hospitalization for all-cause pneumonia [0.85 (0.82–0.89)]. Longer cumulative duration and higher cumulative dose of pioglitazone were associated with further lower adjusted hazard ratios in these outcomes compared to no-use of TZDs. DISCUSSION: This cohort study demonstrated that TZD use was associated with significantly lower risks of hospitalization for pneumonia, invasive mechanical ventilation, and death due to pneumonia in patients with T2D. Higher cumulative duration and dose of pioglitazone were associated with a further lower risk of outcomes. Frontiers Media S.A. 2023-02-17 /pmc/articles/PMC9981669/ /pubmed/36876083 http://dx.doi.org/10.3389/fmicb.2023.1118000 Text en Copyright © 2023 Yen, Wei, Hung, Hsu, Hwu and Hsu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Yen, Fu-Shun
Wei, James Cheng-Chung
Hung, Yu-Tung
Hsu, Chung Y.
Hwu, Chii-Min
Hsu, Chih-Cheng
Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
title Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
title_full Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
title_fullStr Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
title_full_unstemmed Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
title_short Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
title_sort thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981669/
https://www.ncbi.nlm.nih.gov/pubmed/36876083
http://dx.doi.org/10.3389/fmicb.2023.1118000
work_keys_str_mv AT yenfushun thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes
AT weijameschengchung thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes
AT hungyutung thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes
AT hsuchungy thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes
AT hwuchiimin thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes
AT hsuchihcheng thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes